Shares of Teleflex Incorporated (NYSE:TFX) have been given an average rating of “Buy” by the eleven analysts that are currently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $386.11.
Several research analysts recently commented on TFX shares. Leerink Swann set a $405.00 price target on Teleflex and gave the stock a “buy” rating in a research report on Wednesday, September 4th. ValuEngine lowered Teleflex from a “buy” rating to a “hold” rating in a research report on Tuesday, September 10th. JMP Securities boosted their target price on Teleflex from $325.00 to $395.00 and gave the company a “market outperform” rating in a research report on Monday, August 5th. Raymond James dropped their target price on Teleflex from $420.00 to $415.00 and set a “strong-buy” rating for the company in a research report on Monday, October 7th. Finally, Svb Leerink boosted their target price on Teleflex from $395.00 to $405.00 and gave the company an “outperform” rating in a research report on Wednesday, September 4th.
Teleflex stock opened at $353.34 on Monday. The company has a quick ratio of 1.44, a current ratio of 2.33 and a debt-to-equity ratio of 0.72. The company has a market capitalization of $16.36 billion, a P/E ratio of 35.69, a PEG ratio of 2.22 and a beta of 0.95. The stock’s 50 day moving average is $336.19 and its 200 day moving average is $334.69. Teleflex has a twelve month low of $226.02 and a twelve month high of $373.90.
The firm also recently announced a dividend, which will be paid on Monday, December 16th. Shareholders of record on Friday, November 15th will be given a dividend of $0.34 per share. The ex-dividend date of this dividend is Thursday, November 14th. Teleflex’s dividend payout ratio (DPR) is presently 13.74%.
In related news, Director Benson Smith sold 8,500 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $340.00, for a total value of $2,890,000.00. Following the completion of the sale, the director now owns 57,309 shares in the company, valued at $19,485,060. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Stephen K. M.D. Klasko sold 200 shares of the business’s stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $316.01, for a total value of $63,202.00. Following the completion of the sale, the director now owns 936 shares of the company’s stock, valued at approximately $295,785.36. The disclosure for this sale can be found here. Insiders have sold 85,881 shares of company stock valued at $29,096,656 in the last 90 days. Company insiders own 2.36% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Orrstown Financial Services Inc. purchased a new stake in shares of Teleflex in the third quarter valued at approximately $35,000. Atlas Capital Advisors LLC purchased a new stake in shares of Teleflex in the third quarter valued at approximately $39,000. Harvest Fund Management Co. Ltd purchased a new stake in shares of Teleflex in the second quarter valued at approximately $46,000. CSat Investment Advisory L.P. boosted its holdings in shares of Teleflex by 97.4% in the second quarter. CSat Investment Advisory L.P. now owns 150 shares of the medical technology company’s stock valued at $50,000 after purchasing an additional 74 shares during the period. Finally, Cullen Frost Bankers Inc. purchased a new stake in shares of Teleflex in the second quarter valued at approximately $52,000. Hedge funds and other institutional investors own 90.07% of the company’s stock.
Teleflex Company Profile
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Further Reading: What are the qualifications of a portfolio manager?
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.